Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Andrew Yuon, Fong"'
Autor:
Jessie Sze Wing Tse, Wenying Piao, Sharon Suet Man Chan, Yuchen Liu, Alexandria Lau, Vivian Wai Yan Lui, Hui Li, Chin Wang Lau, Hoi Lam Ngan, Jason Y. K. Chan, Yu-xiong Su, Andrew Yuon Fong, Peony Hiu Yan Poon, Kwok Wai Lo, Jennifer R. Grandis, Chun Kit Yeung, Gordon B. Mills, Sze Man Chan
Publikováno v:
Life science alliance, vol 3, iss 6
Life Science Alliance
Life Science Alliance
MAPK mutations favor HNSCC survival, revealing the broad clinical utility of MAPK pathway mutations in prognosis and potentially in precision immunotherapy.
MAPK pathway mutations affect one-fifth of head and neck squamous cell carcinoma (HNSCC)
MAPK pathway mutations affect one-fifth of head and neck squamous cell carcinoma (HNSCC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87751b7eea02b245459c14acc200e62f
https://escholarship.org/uc/item/0gd0s96r
https://escholarship.org/uc/item/0gd0s96r
Autor:
Nick Ka Ming Yau, Ian C. K. Wong, Qin Ying Lim, Vivian Wai Yan Lui, Krista Roberta Verhoeft, WY Lam, Andrew Yuon Fong, Hiu Fung Leung
Publikováno v:
Current Cancer Drug Targets. 15:327-336
The anaplastic lymphoma kinase (ALK) is a druggable target for cancer therapy. By and large, the oncogenic activation of ALK in human tumors is known to occur by gene rearrangement (e.g. EML4-ALK, NMP-ALK, etc.). Clinical use of ALK inhibitors for "A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f774a8ebf25865e3f7907bc1404b68b7
https://doi.org/10.2174/1568009615666150225123712
https://doi.org/10.2174/1568009615666150225123712
Autor:
Hoi-Lam Ngan, Shing Chun Yu, Vivian Wai Yan Lui, Andrew Yuon Fong, Sharon Suet Man Chan, Laura Ren Huey Ip, Jennifer R. Grandis
Publikováno v:
Cancer Research. 78:4278-4278
Somatic mutations of the MAPK pathway occur in ~14% of head and neck squamous cell carcinoma (HNSCC; TCGA Provisional; www.cbioportal.org). Notably, mutations found in MAPK signaling components are apparent hotspot or activating mutations, potentiall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::538b3c8a7bdd7b663d822a69ff3bc8ab
https://doi.org/10.1158/1538-7445.am2018-4278
https://doi.org/10.1158/1538-7445.am2018-4278
Autor:
Nick Ka Ming, Yau, Andrew Yuon, Fong, Hiu Fung, Leung, Krista Roberta, Verhoeft, Qin Ying, Lim, Wai Yip, Lam, Ian Chi Kei, Wong, Vivian Wai Yan, Lui
Publikováno v:
Current cancer drug targets. 15(4)
The anaplastic lymphoma kinase (ALK) is a druggable target for cancer therapy. By and large, the oncogenic activation of ALK in human tumors is known to occur by gene rearrangement (e.g. EML4-ALK, NMP-ALK, etc.). Clinical use of ALK inhibitors for "A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d57f1ff37f98d4f2c1b3633d6977e7c9
https://pubmed.ncbi.nlm.nih.gov/25714698
https://pubmed.ncbi.nlm.nih.gov/25714698